세계의 불활화 백신 시장 보고서(2025년)

Inactivated Vaccines Global Market Report 2025

US $ 4,490 ￦ 6,222,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,993,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,765,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

불활성화 백신 시장 규모는 향후 몇 년 동안 안정적인 성장세를 보일 것으로 예상되며, 2029년까지 4.7%의 연평균 복합 성장률(CAGR)로 77억 5,000만 달러에 달할 것으로 예측됩니다. 예측 기간의 성장은 팬데믹 대비, 백신 적용 범위 확대, 바이오 제조의 발전, 건강 형평성에 대한 노력에 기인하는 것으로 보입니다. 예측 기간 동안 주요 동향으로는 RNA 백신 플랫폼, 혼합 백신, 내열성 백신, 디지털 백신 패스포트 등이 있습니다.

감염성 질환 증가는 향후 불활성화 백신 시장의 성장을 견인할 것으로 예상됩니다. 감염성 질환은 세균, 바이러스, 곰팡이, 기생충 등의 병원체에 의해 유발되는 질병으로, 사람에서 사람으로 전염되어 다양한 증상과 건강상의 합병증을 유발합니다. 결핵이 그 한 예입니다. 불활성화 백신은 비생물성 병원체를 이용해 면역반응을 일으켜 소아마비, A형 간염, 독감 등의 질병을 효과적으로 예방할 수 있습니다. 예를 들어, 2023년 11월 미국 질병통제예방센터(CDC)는 미국 내 결핵 환자 수가 2022년 8,320명에서 2023년 9,615명으로 1,295명 증가했다고 보고했습니다. 따라서 감염병의 확산이 불활성화 백신 시장 확대에 박차를 가하고 있습니다.

예방접종 이니셔티브 증가는 향후 몇 년 동안 불활성화 백신 시장의 성장을 가속할 것으로 예상됩니다. 예방접종 이니셔티브에는 특정 감염성 질환에 대한 예방접종을 개인과 지역사회에 제공하고 궁극적으로 이러한 건강 위협으로부터 사람들을 보호하기 위한 조직적인 캠페인과 노력이 포함됩니다. 예방접종 이니셔티브의 확대는 불활성화 백신 시장의 중요한 요소로 작용하고 있습니다. 예방접종 캠페인의 확산은 불활성화 백신에 대한 수요를 증가시키고, 시장 개척을 촉진하며, 연구개발에 대한 투자를 촉진합니다. 예를 들어, 스위스에 본부를 둔 정부 간 기구인 세계보건기구(WHO)의 데이터에 따르면, 백신이 간염, 디프테리아, 파상풍, 백일해, 홍역, 소아마비 등 감염성 질환으로 인해 매년 400만-500만 명의 목숨을 잃는 것을 예방하고 있다고 합니다. 또한, 2022년에는 전 세계 영유아의 약 84%가 소아마비 백신을 3회 접종할 것으로 예상됩니다. 마찬가지로, 경구용 소아마비 백신(OPV)을 사용하는 국가에서는 약 84%의 영유아가 같은 해에 불활성화 소아마비 백신(IPV)을 처음 접종할 것으로 추정됩니다. 따라서 예방접종에 대한 관심이 높아지면서 불활성화 백신 시장 확대의 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 불활화 백신 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업 분석
• 세계의 불활화 백신 시장 : 성장률 분석
• 세계의 불활화 백신 시장 실적 : 규모와 성장, 2019-2024
• 세계의 불활화 백신 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 불활화 백신 전체 시장(TAM)

제6장 시장 세분화

• 세계의 불활화 백신 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 바이러스 백신
• 세균 백신
• 세계의 불활화 백신 시장 불활성화 방법, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 용제 세제
• 방사선
• pH 농도
• 열 불활성화
• 기타 불활성화 방법
• 세계의 불활화 백신 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원 약국
• 소매 약국
• 기타 유통 채널
• 세계의 불활화 백신 시장 : 바이러스 백신 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 불활성화 폴리오 바이러스 백신(IPV)
• 불활성화 인플루엔자 백신
• 불활성화 A형 간염 백신
• 불활성화 광견병 백신
• 세계의 불활화 백신 시장 세균 백신 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 불활성화 장티푸스 백신
• 불활성화 콜레라 백신
• 불활성화 백일해 백신
• 불활성화 페스트 백신

제7장 지역별/국가별 분석

• 세계의 불활화 백신 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 불활화 백신 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 불활화 백신 시장 : 경쟁 구도
• 불활화 백신 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sinopharm Group Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Astellas Pharma Inc.
• CSL Limited
• Daiichi Sankyo Company Limited
• Mitsubishi Tanabe Pharma Corporation
• Novavax Inc.
• Zydus Lifesciences Ltd.
• Sinovac Biotech Ltd.
• Biological E Limited
• Hualan Biological Engineering Inc.
• CanSino Biologics Inc.
• Shenzhen Kangtai Biological Products Co. Ltd.
• Serum Institute of India Pvt. Ltd.
• Beijing Tiatan Biological Products Co. Ltd.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 불활화 백신 시장(2029년) : 새로운 기회를 제공하는 국가
• 불활화 백신 시장(2029년) : 새로운 기회를 제공하는 부문
• 불활화 백신 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Inactivated vaccines, also known as killed vaccines, belong to a category of vaccines that contain viruses or bacteria that have been rendered nonfunctional or inactivated through methods like heat, chemicals, or radiation. These vaccines are specifically developed to elicit an immune response in the vaccinated individual without causing the disease itself.

The primary categories of inactivated vaccines include viral and bacterial vaccines. Viral vaccines are biological preparations containing weakened or inactivated virus components that serve to stimulate the immune system and provide immunity against the targeted viral infection. These viruses are rendered nonfunctional through processes such as solvent detergent treatment, radiation, pH adjustment, heat inactivation, and other methods. These vaccines are typically distributed through hospital pharmacies, retail pharmacies, and other relevant channels.

The inactivated vaccines market research report is one of a series of new reports from The Business Research Company that provides inactivated vaccines market statistics, including inactivated vaccines industry global market size, regional shares, competitors with an inactivated vaccines market share, detailed inactivated vaccines market segments, market trends and opportunities and any further data you may need to thrive in the inactivated vaccines industry. This inactivated vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The inactivated vaccines market size has grown steadily in recent years. It will grow from $6.19 billion in 2024 to $6.44 billion in 2025 at a compound annual growth rate (CAGR) of 4.0%. The growth in the historic period can be attributed to polio eradication efforts, influenza vaccination programs, emerging infectious diseases, regulatory approvals.

The inactivated vaccines market size is expected to see steady growth in the next few years. It will grow to $7.75 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to pandemic preparedness, expanding vaccine coverage, biomanufacturing advancements, health equity initiatives. Major trends in the forecast period include mrna vaccine platforms, combination vaccines, thermostable vaccines, digital vaccine passports.

The rising prevalence of infectious diseases is expected to drive the growth of the inactivated vaccine market in the future. Infectious diseases are illnesses caused by pathogens such as bacteria, viruses, fungi, or parasites, which can spread from one person to another, leading to various symptoms and health complications. Tuberculosis is an example of such diseases. Inactivated vaccines use non-living pathogens to trigger an immune response, effectively preventing illnesses like polio, hepatitis A, and influenza. For example, in November 2023, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, reported an increase in the number of tuberculosis cases in the U.S., rising from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Therefore, the growing prevalence of infectious diseases is fueling the expansion of the inactivated vaccine market.

The increasing immunization initiatives are poised to foster the growth of the inactivated vaccines market in the coming years. Immunization initiatives encompass organized campaigns and efforts designed to vaccinate individuals or communities against specific infectious diseases, ultimately shielding them from these health threats. The expansion of immunization initiatives constitutes a significant factor in the inactivated vaccines market. The proliferation of vaccination campaigns results in higher demand for inactivated vaccines, thereby stimulating market growth and encouraging investments in research and development. For instance, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicates that vaccines annually prevent 4-5 million lives from being lost globally due to infectious diseases like hepatitis, diphtheria, tetanus, pertussis (whooping cough), measles, and polio. Furthermore, in 2022, approximately 84% of infants worldwide received three doses of the polio vaccine. Similarly, an estimated 84% of infants in countries utilizing oral polio vaccine (OPV) received their initial inactivated polio vaccine (IPV) dose during the same year. Consequently, the growing immunization initiatives are a driving force behind the expansion of the inactivated vaccines market.

Prominent companies engaged in the inactivated vaccines market are introducing cutting-edge and advanced inactivated vaccines to maintain their market positioning. Inactivated vaccines encompass vaccines containing non-live virus particles, bacteria, or other pathogens that have been cultured and subsequently rendered non-viable to eliminate their disease-causing capabilities. As an illustration, in January 2022, GSK PLC, a UK-based pharmaceutical and biotechnology enterprise, unveiled a novel inactivated vaccine known as Shingrix, designed for shingles protection. Shingrix is a non-live, recombinant subunit adjuvanted vaccine administered via intramuscular injection in two doses. Initially indicated for individuals aged 50 and older, its application has recently been expanded to encompass individuals aged 18 and older who face an elevated risk of developing shingles due to immunodeficiency or immunosuppression triggered by a known medical condition or medical treatment.

In April 2022, Albumedix Ltd., a UK-based biotechnology company, forged a collaboration with Valneva SE. This collaborative venture between Albumedix Ltd. and Valneva is expected to contribute to an augmentation in the production capacity of inactivated COVID-19 vaccines. The increased production capacity is intended to cater to the escalating demand for COVID-19 vaccines. Valneva SE is a French biotechnology enterprise with expertise in the discovery, manufacture, and distribution of inactivated vaccines designed to combat infectious diseases.

Major companies operating in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd.,.

North America was the largest region in the inactivated vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inactivated vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The inactivated vaccines market consists of sales of whole-cell inactivated vaccines, subunit or protein subunit vaccines, conjugate vaccines and toxoid vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inactivated Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inactivated vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inactivated vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inactivated vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Viral Vaccine; Bacterial Vaccine
• 2) By Method Of Inactivation: Solvent Detergent; Radiation; pH Concentration; Heat Inactivation; Other Methods Of Inactivation
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
• Subsegments:
• 1) By Viral Vaccine: Inactivated Poliovirus Vaccine (IPV); Inactivated Influenza Vaccine; Inactivated Hepatitis A Vaccine; Inactivated Rabies Vaccine
• 2) By Bacterial Vaccine: Inactivated Typhoid Vaccine; Inactivated Cholera Vaccine; Inactivated Pertussis Vaccine; Inactivated Plague Vaccine
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Sinopharm Group Co. Ltd.; Merck & Co. Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inactivated Vaccines Market Characteristics

3. Inactivated Vaccines Market Trends And Strategies

4. Inactivated Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Inactivated Vaccines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Inactivated Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Inactivated Vaccines Market Growth Rate Analysis
• 5.4. Global Inactivated Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Inactivated Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Inactivated Vaccines Total Addressable Market (TAM)

6. Inactivated Vaccines Market Segmentation

• 6.1. Global Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Viral Vaccine
• Bacterial Vaccine
• 6.2. Global Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Solvent Detergent
• Radiation
• pH Concentration
• Heat Inactivation
• Other Methods Of Inactivation
• 6.3. Global Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.4. Global Inactivated Vaccines Market, Sub-Segmentation Of Viral Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Poliovirus Vaccine (IPV)
• Inactivated Influenza Vaccine
• Inactivated Hepatitis A Vaccine
• Inactivated Rabies Vaccine
• 6.5. Global Inactivated Vaccines Market, Sub-Segmentation Of Bacterial Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inactivated Typhoid Vaccine
• Inactivated Cholera Vaccine
• Inactivated Pertussis Vaccine
• Inactivated Plague Vaccine

7. Inactivated Vaccines Market Regional And Country Analysis

• 7.1. Global Inactivated Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Inactivated Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inactivated Vaccines Market

• 8.1. Asia-Pacific Inactivated Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inactivated Vaccines Market

• 9.1. China Inactivated Vaccines Market Overview
• 9.2. China Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inactivated Vaccines Market

• 10.1. India Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inactivated Vaccines Market

• 11.1. Japan Inactivated Vaccines Market Overview
• 11.2. Japan Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inactivated Vaccines Market

• 12.1. Australia Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inactivated Vaccines Market

• 13.1. Indonesia Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inactivated Vaccines Market

• 14.1. South Korea Inactivated Vaccines Market Overview
• 14.2. South Korea Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inactivated Vaccines Market

• 15.1. Western Europe Inactivated Vaccines Market Overview
• 15.2. Western Europe Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inactivated Vaccines Market

• 16.1. UK Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inactivated Vaccines Market

• 17.1. Germany Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inactivated Vaccines Market

• 18.1. France Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inactivated Vaccines Market

• 19.1. Italy Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inactivated Vaccines Market

• 20.1. Spain Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inactivated Vaccines Market

• 21.1. Eastern Europe Inactivated Vaccines Market Overview
• 21.2. Eastern Europe Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inactivated Vaccines Market

• 22.1. Russia Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inactivated Vaccines Market

• 23.1. North America Inactivated Vaccines Market Overview
• 23.2. North America Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inactivated Vaccines Market

• 24.1. USA Inactivated Vaccines Market Overview
• 24.2. USA Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inactivated Vaccines Market

• 25.1. Canada Inactivated Vaccines Market Overview
• 25.2. Canada Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inactivated Vaccines Market

• 26.1. South America Inactivated Vaccines Market Overview
• 26.2. South America Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inactivated Vaccines Market

• 27.1. Brazil Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inactivated Vaccines Market

• 28.1. Middle East Inactivated Vaccines Market Overview
• 28.2. Middle East Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inactivated Vaccines Market

• 29.1. Africa Inactivated Vaccines Market Overview
• 29.2. Africa Inactivated Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Inactivated Vaccines Market, Segmentation By Method Of Inactivation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Inactivated Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inactivated Vaccines Market Competitive Landscape And Company Profiles

• 30.1. Inactivated Vaccines Market Competitive Landscape
• 30.2. Inactivated Vaccines Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sinopharm Group Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Inactivated Vaccines Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Astellas Pharma Inc.
• 31.4. CSL Limited
• 31.5. Daiichi Sankyo Company Limited
• 31.6. Mitsubishi Tanabe Pharma Corporation
• 31.7. Novavax Inc.
• 31.8. Zydus Lifesciences Ltd.
• 31.9. Sinovac Biotech Ltd.
• 31.10. Biological E Limited
• 31.11. Hualan Biological Engineering Inc.
• 31.12. CanSino Biologics Inc.
• 31.13. Shenzhen Kangtai Biological Products Co. Ltd.
• 31.14. Serum Institute of India Pvt. Ltd.
• 31.15. Beijing Tiatan Biological Products Co. Ltd.

32. Global Inactivated Vaccines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inactivated Vaccines Market

34. Recent Developments In The Inactivated Vaccines Market

35. Inactivated Vaccines Market High Potential Countries, Segments and Strategies

• 35.1 Inactivated Vaccines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Inactivated Vaccines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Inactivated Vaccines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료